Literature DB >> 10398404

Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies.

S Muyldermans1, M Lauwereys.   

Abstract

The humoral immune response of camels, dromedaries and llamas includes functional antibodies formed by two heavy chains and no light chains. The amino acid sequence of the variable domain of the naturally occurring heavy-chain antibodies reveals the necessary adaptations to compensate for the absence of the light chain. In contrast to the conventional antibodies, a large proportion of the heavy-chain antibodies acts as competitive enzyme inhibitors. Studies on the dromedary immunoglobulin genes start to shed light on the ontogeny of these heavy-chain antibodies. The presence of the heavy-chain antibodies and the possibility of immunizing a dromedary allows for the production of antigen binders consisting of a single domain only. These minimal antigen-binding fragments are well expressed in bacteria, bind the antigen with affinity in the nM range and are very stable. We expect that such camelid single domain antibodies will find their way into a number of biotechnological or medical applications. The structure of the camelid single domain is homologous to the human VH, however, the antigen-binding loop structures deviate fundamentally from the canonical structures described for human or mouse VHs. This has two additional advantages: (1) the camel or llama derived single domain antibodies might be an ideal scaffold for anti-idiotypic vaccinations; and (2) the development of smaller peptides or peptide mimetic drugs derived from of the antigen binding loops might be facilitated due to their less complex antigen binding site. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398404     DOI: 10.1002/(SICI)1099-1352(199903/04)12:2<131::AID-JMR454>3.0.CO;2-M

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  29 in total

1.  Single-domain antibody fragments with high conformational stability.

Authors:  Mireille Dumoulin; Katja Conrath; Annemie Van Meirhaeghe; Filip Meersman; Karel Heremans; Leon G J Frenken; Serge Muyldermans; Lode Wyns; Andre Matagne
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

Review 2.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

3.  High affinity anti-inorganic material antibody generation by integrating graft and evolution technologies: potential of antibodies as biointerface molecules.

Authors:  Takamitsu Hattori; Mitsuo Umetsu; Takeshi Nakanishi; Takanari Togashi; Nozomi Yokoo; Hiroya Abe; Satoshi Ohara; Tadafumi Adschiri; Izumi Kumagai
Journal:  J Biol Chem       Date:  2009-12-31       Impact factor: 5.157

4.  Analysis and modeling of the variable region of camelid single-domain antibodies.

Authors:  Aroop Sircar; Kayode A Sanni; Jiye Shi; Jeffrey J Gray
Journal:  J Immunol       Date:  2011-04-27       Impact factor: 5.422

5.  Characterization of camel nanobodies specific for superfolder GFP fusion proteins.

Authors:  Aya Twair; Souad Al-Okla; Moutaz Zarkawi; Abdul Qader Abbady
Journal:  Mol Biol Rep       Date:  2014-08-02       Impact factor: 2.316

Review 6.  Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Authors:  Nairo Brilhante-da-Silva; Rosa Maria de Oliveira Sousa; Andrelisse Arruda; Eliza Lima Dos Santos; Anna Carolina Machado Marinho; Rodrigo Guerino Stabeli; Carla Freire Celedonio Fernandes; Soraya Dos Santos Pereira
Journal:  Mol Diagn Ther       Date:  2021-06-19       Impact factor: 4.074

Review 7.  50 Years of Structural Immunology.

Authors:  Ian A Wilson; Robyn L Stanfield
Journal:  J Biol Chem       Date:  2021-05-03       Impact factor: 5.157

8.  Interaction standards for biophysics: anti-lysozyme nanobodies.

Authors:  Holly L Birchenough; Hilda D Ruiz Nivia; Thomas A Jowitt
Journal:  Eur Biophys J       Date:  2021-04-11       Impact factor: 1.733

9.  Natural and man-made V-gene repertoires for antibody discovery.

Authors:  William J J Finlay; Juan C Almagro
Journal:  Front Immunol       Date:  2012-11-15       Impact factor: 7.561

10.  Receptor-mediated endocytosis and brain delivery of therapeutic biologics.

Authors:  Guangqing Xiao; Liang-Shang Gan
Journal:  Int J Cell Biol       Date:  2013-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.